As the third most common malignancy and the second most deadly cancer, colorectal
cancer (CRC) induces estimated 1.9 million incidence cases and 0.9 million deaths …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Rapid and efficient tools for early cancer detection have diagnostic and therapeutic value.
Given that the DNA hairpin‐based hybridization chain reaction (HCR) is effective in …

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …

Circular RNAs (circRNAs), covalently closed noncoding RNAs, are widely expressed in
eukaryotes and viruses. They can function by regulating target gene expression, linear RNA …

Departments of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical
School, Tokyo, Japan Colorectal cancer (CRC) is the third most common cancer worldwide …

Nanotechnology is reshaping health care strategies and is expected to exert a tremendous
impact in the coming years offering better healthcare facilities. It has led to not only …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Colorectal cancer (CRC) is a highly heterogeneous cancer and exploring novel therapeutic
options is a pressing issue that needs to be addressed. Here, we established human CRC …

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide.
The primary treatment for CRC is surgical resection, along with chemotherapy in more …